$4.06
+0.18 (+4.64%)
Open$4.03
Previous Close$3.88
Day High$4.11
Day Low$3.88
52W High$11.88
52W Low$2.14
Volume—
Avg Volume69.0K
Market Cap84.74M
P/E Ratio—
EPS$-2.21
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+463.8% upside
Current
$4.06
$4.06
Target
$22.89
$22.89
$19.41
$22.89 avg
$38.59
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.76M | 20.47M | 20.59M |
| Net Income | 3.46M | 2.44M | 2.89M |
| Profit Margin | 15.9% | 11.9% | 14.1% |
| EBITDA | 6.13M | 5.18M | 5.24M |
| Free Cash Flow | 2.45M | 2.75M | 2.72M |
| Rev Growth | +16.8% | +12.7% | +4.6% |
| Debt/Equity | 0.77 | 0.70 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |